- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01283360
Microbicide Safety and Acceptability in Young Men (Project Gel)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Microbicides are products that can be applied in the vagina or rectum to decrease the chances of transmission of sexually transmitted infections (STIs) including HIV. In the US, one of the most vulnerable groups for acquiring HIV infection is young men, especially young Black and Latino men who have sex with men (MSM). This study will be conducted with a young 18-30 year-old ethnically diverse sample of HIV-negative MSM who report engaging in receptive anal intercourse (RAI) using condoms inconsistently or not at all. Our goal is to test whether patterns of use of a placebo rectal gel prior to RAI suggest that the product would be used correctly and consistently in real life circumstances and whether this highly vulnerable population could safely use tenofovir gel, a microbicide candidate. In Version 3.0 of this multicentered protocol, a cohort of 40 male and transgender female sex workers were added to Stages 1A and 1B in order to determine the feasibility of recruitment and retention of men who have sex with men (MSM) with high risk sexual behavior, such as sex workers, for microbicide studies, and their likelihood to use noncondom based HIV prevention strategies. This study will be conducted by the University of Pittsburgh in collaboration with researchers at the HIV Center for Clinical and BehavioralStudies at Columbia University; the Fenway Community Health in Boston; and the University of Puerto Rico Clinical Trial Unit in San Juan, Puerto Rico. Subjects will be enrolled at the University of Pittsburgh, Fenway Community Health, and the University of Puerto Rico. This is a two-stage longitudinal study including a clinical and behavioral evaluation (Stage 1A) with an acceptability and adherence trial (Stage 1B), followed by a Phase 1 randomized, double-blind, multi-site, placebo-controlled trial (Stage 2). Participants who complete Stage 1A are eligible to be selected for enrollment into Stage 1B; a similar transition occurs between Stage 1B and Stage 2.
- In Stage 1A, approximately 280 MSM between the ages of 18-30 will be enrolled, including a subset of 40 sex workers and will undergo a baseline medical evaluation and a detailed Web-based baseline behavioral assessment.
- In Stage 1B, approximately 140 participants from Satge 1A, including a subset of 20 sex workers, will be asked to apply a placebo gel (HEC) rectally prior to each episode of RAI over a 3-month period, reporting each use via a phone reporting system. At the end of the 3 months, participants will complete a Web-based questionnaire and take part in a video teleconference.The first 42 eligible participants, excluding the mal and transgender female sex worker cohort, (approximately 14 at each site) completing Stage 1B with a reported adherence of 80% or greater will be invited to enroll in Stage 2.
- In Stage 2, approximately 24 eligible participants from Stage 1B will progress to Stage 2 and be randomized at a 1:1 ratio to tenofovir 1% gel or HEC placebo gel.Following a baseline visit, participants will return to the clinic, where a single dose of the study gel will be administered. Within approximately 30 minutes, rectal swab, stool, and rectal biopsy specimens will be obtained via anoscopy. After a one-week recovery period participants will return to the clinic for assessment. If no significant adverse events(AEs) are reported they will begin to self-administer once-daily outpatient doses of the study gel for 7 days, after which they will return to the clinic for evaluation and specimen collection.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
San Juan, Puerto Rico, 00936
- University of Puerto Rico Medical Sciences Campus
-
-
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- The Fenway Institute-Fenway Community Health
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria for Participants in Stage 1A (non sex-workers):
- Willing and able to provide written informed consent to take part in the study
- Willing and able to communicate in English or Spanish
- Must agree not to participate in other drug trials
- Biologically male and identifies as male
- Age 18-30 years at screening
- HIV-1 status antibody negative or unknown per patient report
- Understands and agrees to local STI reporting requirements
- Able and willing to provide adequate information for locator purposes
- Availability to return for all study visits, barring unforeseen circumstances
- A history of consensual RAI at least once in past month
- Reporting at least one occasion of unprotected RAI in the prior year* In order to identify participants at increased risk for acquiring HIV
Inclusion Criteria for Participants in Stage 1A (sex-workers):
- Willing and able to provide written informed consent to take part in the study
- Willing and able to communicate in English or Spanish
- Must agree not to participate in other drug trials
- Biologically male, including male-to-female transgender women
- Age 18-30 years at screening
- HIV-1 status antibody negative or unknown per patient report
- Understands and agrees to local STI reporting requirements
- Able and willing to provide adequate information for locator purposes
- Availability to return for all study visits, barring unforeseen circumstances
- A history of consensual RAI at least once in past month
- Reporting at least one occasion of unprotected RAI in the prior year*
Reporting at least two occasions of RAI as part of transactional sex (i.e., having received money or other goods/services in exchange for sex) in the prior 2 months*
- In order to identify participants at increased risk for acquiring HIV
Inclusion Criteria for Participants in Stage 1B (both sex workers and non sex-workers):
- Completed Stage 1A
- HIV-1 uninfected at screening based on HIV rapid test results
- Reports unprotected RAI in the prior three months on at least one occasion* In order to obtain acceptability data from individuals most likely to benefit from microbicide availability
- Availability to return for all Stage 1B visits, barring unforeseen circumstances
Inclusion Criteria for Participants in Stage 2:
- Completed study stage 1AB
- HIV-1 uninfected at screening based on HIV rapid test results
- Availability to return for all Stage 2 visits, barring unforeseen circumstances
Exclusion Criteria for Participants in Stage 1A (both sex workers and non sex-workers):
1. Any condition or prior therapy that, in the opinion of the investigator, would make study participation unsafe, make the individual unsuitable for the study or unable to comply with the study requirements. Such conditions may include, but are not limited to, current or recent history of severe, progressive, or uncontrolled substance abuse, or renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, or cerebral disease
Exclusion Criteria for Participants in Stage 1B (both sex workers and non sex-workers):
- Clinical or laboratory diagnosis of active rectal infection requiring treatment per current CDC guidelines. Infections requiring treatment include Chlamydia (CT), gonorrhea (GC), syphilis, active HSV lesions, chancroid, genital sores or ulcers, and if clinically indicated, genital warts. Note that an HSV-2 seropositive diagnosis with no active lesions is allowed, since treatment is not required
- Positive Hepatitis B surface antigen test indicating hepatitis B infection
- Allergy to methylparaben, propylparaben, or latex
- History of significant drug allergy or recurrent urticaria
- History of inflammatory bowel disease
- Currently engage or plan to engage in unprotected RAI with HIV-infected partners
- By participant report planning to receive another investigational drug while participating in this study
- Any other condition or prior therapy that, in the opinion of the investigator, would make study participation unsafe, make the individual unsuitable for the study or unable to comply with the study requirements. Such conditions may include, but are not limited to, current or recent history of severe, progressive, or uncontrolled substance abuse, or renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, or cerebral disease
Exclusion Criteria for Participants in Stage 2:
- Meet any of the exclusion criteria for Stage 1B
- Reporting a history of transactional sex (i.e., having received money or other goods/services in exchange for sex) in the prior 6 months
- Undergoing or completed gender reassignment
- Grade 2 or higher liver function, creatinine, coagulation, electrolyte, or hematology abnormality in accordance with DAIDS toxicity table values (normal values based on site specific laboratory criteria) at screening (or Visit 2 PT/INR for coagulation), and confirmed by retest/and or redraw
- History of significant gastrointestinal bleeding
- History of inflammatory bowel disease
- Abnormalities of the rectal mucosa, or significant rectal symptom(s), which in the opinion of the clinician represents a contraindication to biopsy (including but not limited to presence of any unresolved injury, infectious or inflammatory condition of the local mucosa, and presence of symptomatic external hemorrhoids
Per participant report, anticipated use and/or unwillingness to abstain from the following medications during the period of Stage 2 study participation:
- Heparin, including Lovenox®
- Warfarin
- Plavix® (clopidogrel bisulfate)
- Aspirin >81 mg per day
- Non-steroidal anti-inflammatory drugs (NSAIDS)
- Any other drugs that are associated with increased likelihood of bleeding following rectal biopsy
- By participant report, use of systemic immunomodulatory medications within the 4 weeks prior to the Stage 2 Enrollment Visit and throughout study participation
- By participant report, use of rectally administered medications, rectally administered products (including condoms) containing N-9, or any investigational products within the 2 weeks or 10 half-lives of the drug, whichever is longer, prior to the Stage 2 Enrollment Visit, or is planning to receive another investigational drug while participating in this study
- Any other condition or prior therapy that, in the opinion of the investigator, would make study participation unsafe, make the individual unsuitable for the study or unable to comply with the study requirements. Such conditions may include, but are not limited to, current or recent history of severe, progressive, or uncontrolled substance abuse, or renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, or cerebral disease -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: HEC Placebo Gel
In Stage 2, participants will be randomized to receive either tenofovir 1% gel or HEC placebo gel.
Following a baseline visit, participants will return to the clinic, where a single dose of the study gel will be administered.
Within approximately 30 minutes, rectal swab, stool, and rectal biopsy specimens will be obtained via anoscopy.
After a one-week recovery period participants will return to the clinic for assessment.
If no significant adverse events (AEs) are reported they will begin to self-administer once-daily outpatient doses of the study gel for 7 days, after which they will return to the clinic for evaluation and specimen collection.
|
The HEC universal placebo gel for Stage 2 will be supplied by CONRAD (Arlington, VA, USA).
Under direction from CONRAD, DPT Laboratories will manufacture the HEC placebo gel and analyze/release the gels under cGMP.
DPT Laboratories will fill the applicators with HEC placebo gel to create pre-filled applicators and package each applicator and plunger in a wrapper.
Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of HEC gel.
|
ACTIVE_COMPARATOR: Tenofovir 1% Gel
In Stage 2, participants will be randomized to receive either tenofovir 1% gel or HEC placebo gel.
Following a baseline visit, participants will return to the clinic, where a single dose of the study gel will be administered.
Within approximately 30 minutes, rectal swab, stool, and rectal biopsy specimens will be obtained via anoscopy.
After a one-week recovery period participants will return to the clinic for assessment.
If no significant adverse events (AEs) are reported they will begin to self-administer once-daily outpatient doses of the study gel for 7 days, after which they will return to the clinic for evaluation and specimen collection.
|
Tenofovir 1% gel will be supplied by CONRAD (Arlington, VA, USA).
Under direction from CONRAD, DPT Laboratories will manufacture the tenofovir 1% gel and analyze/release the gels under cGMP.
DPT Laboratories will fill the applicators designed for vaginal use with tenofovir 1% gel to create pre-filled applicators and package each applicator and plunger in a wrapper.
Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of tenofovir 1% gel (equal to 4.4 g).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stage 1AB Primary behavioral outcomes
Time Frame: 3 months
|
|
3 months
|
Stage 1AB Primary clinical outcome
Time Frame: 3 months
|
the presence of STIs and anal and rectal pathologies as detected by standard anoscopy
|
3 months
|
Stage 2 Primary clinical outcomes
Time Frame: 6 months
|
Grade 2 or higher AEs, as defined by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, Dec 2004 and/or Addenda 3 (Rectal Grading Tables for Use in Microbicide Studies).
|
6 months
|
Stage 2 Behavioral
Time Frame: 6 months
|
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stage 1AB Secondary clinical endpoint
Time Frame: 3 months
|
Percent of agreement between reports of anal and rectal pathologies by two assessment methods (standard anoscopy versus high-resolutions anoscopy).
|
3 months
|
Stage 2 Secondary behavioral outcomes
Time Frame: 6 months
|
|
6 months
|
Stage 1AB Secondary behavioral outcomes
Time Frame: 3 months
|
|
3 months
|
Stage 2 Behavioral
Time Frame: 6 months
|
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stage 1AB Tertiary Behavioral
Time Frame: 3 months
|
|
3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ian McGowan, MD, PhD, University of Pittsburgh
- Principal Investigator: Alex Carballo-Dieguez, PhD, New York State Psychiatric Institute and Columbia University
- Study Director: Lynne M. Mofensen, MD, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1009001
- Grant #:1R01HD059533-01A1 (OTHER_GRANT: NICHD)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Negative
-
National Institute of Allergy and Infectious Diseases...CompletedInnate Immunity | HIV Negative | Adaptive ImmunityUnited States
-
California State University, Dominguez HillsRecruitingHIV Negative and Not Yet on PrEPUnited States
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
Clinton Health Access Initiative Inc.Heidelberg University; World Health Organization; Ministry of Health, Swaziland; Mylan LaboratoriesCompletedHIV Negative People Identified at Substantial Risk for HIV InfectionSwaziland
-
St George's, University of LondonPublic Health EnglandRecruitingHIV/AIDS | Meningococcal DiseaseUnited Kingdom
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast CarcinomaUnited States
-
University of Southern CaliforniaCompletedHIV Infections | Salmonella InfectionsUnited States
-
St George's, University of LondonUnknownHIV Infections | Hiv | Meningitis, MeningococcalUnited Kingdom
-
Roswell Park Cancer InstituteAIM ImmunoTech Inc.CompletedEstrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple -Negative Breast Cancer | Anatomic Stage IV Breast Cancer AJCCUnited States
-
University of WashingtonTerminatedEstrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7United States
Clinical Trials on HEC Placebo Gel
-
BiosynNational Institute of Allergy and Infectious Diseases (NIAID)UnknownHIV InfectionsUnited States
-
BiosynNational Institute of Allergy and Infectious Diseases (NIAID)Unknown
-
CONRADCompleted
-
CONRADCompleted
-
Starpharma Pty LtdNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompletedHealthyUnited States, Puerto Rico
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute of Mental Health...CompletedHIV InfectionsUnited States, Puerto Rico
-
CONRADWithdrawn
-
Population CouncilCompleted
-
CONRADRTI International; Match Research; UZ-UCSF Collaborative Research ProgrammeCompletedHIV | ContraceptionSouth Africa, Zimbabwe
-
International Partnership for Microbicides, Inc.Withdrawn